• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

特罗凯联合多西他赛治疗肝细胞癌和胆道癌的临床实验

[复制链接]
8117 6 bluest 发表于 2012-8-16 17:17:54 |

马上注册,结交更多好友,享用更多功能,让你轻松玩转社区。

您需要 登录 才可以下载或查看,没有账号?立即注册

x
Background
Patients with advanced hepatocellular (HCC) and biliary tract carcinomas (BTC) have poor prognosis. While the EGFR pathway is overactive in HCC and BTC, single agent anti-EGFR therapies confer modest activity. Preclinical data showed synergistic antiproliferative and proapoptotic effects between anti-EGFR therapies and taxanes. We conducted a phase I study of erlotinib and docetaxel in solid tumors, and noted good tolerability and sustained complete (5 years +) and partial responses in patients with HCC and BTC. This trial evaluated the efficacy of erlotinib with docetaxel in refractory hepatobiliary cancers.

Methods
Eligible patients were allowed to have two prior systemic therapies. Docetaxel 30 mg/m2 i.v. was administered on days 1, 8, 15, and erlotinib 150 mg was dosed orally on days 2–7, 9–14, 16–28 of each 28-day cycle. The primary endpoint was 16 weeks progression-free survival (PFS), and secondary endpoints included response, stable disease, and overall survival. Tumor samples were analyzed for KRAS gene mutations and E-cadherin expression by immunohistochemistry (IHC). Patients with BTC and HCC were accrued and assessed in separate strata for the efficacy endpoints, but for the two-stage initial design of the study, combined PFS was considered. A Simon optimal two-stage design tested the hypothesis that the 16-week PFS is < 15% (clinically inactive) versus the alternative of ≥ 30% (warranting further study).

Results
Twenty-five patients, 14 with HCC and 11 with BTC, were enrolled. Common toxicities were rash (76%), diarrhea (56%), and fatigue (52%), mostly grade 1 or 2. No objective responses were seen. Seven BTC (64%) and 6 HCC patients (46%) had stable disease as best response, with a median duration of 16.1 weeks (95% CI 3.7–56.3) for BTC, and 17.6 weeks (95% CI 8.1–49.8) for HCC. The 16-week PFS was 64% for BTC (95% CI 29.7–84.5), and 38% for HCC (95% CI 14.1–62.8). Median overall survival was 5.7 and 6.7 months for BTC and HCC patients, respectively. BTC patients with grade ≥ 2 rash had higher median PFS (6.2 vs 2.2 months) and OS (14.2 vs 4.2 months). HCC patients with negative/low E-cadherin expression had higher median PFS (6.7 vs 2.1 months) and OS (14.5 vs 4 months).

Conclusions
Erlotinib with docetaxel met the 16-week PFS ≥ 30% endpoint, but overall survival was comparable to that seen with single-agent erlotinib. With the limitation of  small numbers of patients, grade ≥ 2 rash (in BTC), and negative/low E-cadherin expression (HCC) were associated with higher PFS and OS.

胆道癌部分:64%稳定,36%进展,中位无进展期4.7个月。
剂量:特罗凯每天150mg; 多西他赛30mg/平米(第1,8,15天)

http://clinicaltrialreports.theo ... t11-253ctr-chiorean
http://clinicaltrials.gov/ct2/sh ... ocetaxel&rank=6
深度读帖后再提问,在线时间过短不予回复。
所有信息仅供参考!

6条精彩回复,最后回复于 2017-12-20 00:16

山水  初中二年级 发表于 2012-8-16 19:56:12 | 显示全部楼层 来自: 浙江金华
深蓝辛苦了,您的努力惠及你我他!
童言  初中三年级 发表于 2012-8-17 22:05:29 | 显示全部楼层 来自: 山东青岛
辛苦啦深蓝
爱在今生  初中二年级 发表于 2013-3-31 23:02:10 | 显示全部楼层 来自: 北京
学习了,多谢分享前沿医讯

举报 使用道具

回复 支持 0 反对 1
zhangzronghao  高中一年级 发表于 2013-11-21 18:20:27 | 显示全部楼层 来自: 中国
谢谢受益啦

举报 使用道具

回复 支持 0 反对 1
laughrunning  小学二年级 发表于 2017-2-26 22:05:33 | 显示全部楼层 来自: 四川成都
楼主很用功,谢谢您的付出

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表